Navigation Links
Actemra Post-Launch Success Continues to Gain Momentum with Broader Adoption Compared to Biologic Analog Launches and a Professional Marketing Campaign That Resonates with Rheumatologists
Date:8/31/2010

EXTON, Pa., Aug. 31 /PRNewswire/ -- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an inadequate response to one or more TNF-alpha inhibitors. This report is derived from on-line survey responses from 75 rheumatologists and qualitative interviews with a subset of the survey respondents.

Rheumatologists report using Actemra with clinical success in patients who failed one or more TNF-alpha inhibitors despite the need for more frequent blood monitoring of liver function, lipid profile, and neutrophil and platelet counts. Each of these side effect issues has had varying degrees of impact on physicians' treatment patterns.

The breadth and depth of adoption of Actemra is greater than that of other biologic analogs in RA at a six-month post-launch timeframe. Patient origination is largely derived from the three established TNF-alpha inhibitors (Amgen/Pfizer's Enbrel, Abbott's Humira and Centocor Ortho Biotech's Remicade), although rheumatologists consider Actemra to compete more directly with (i.e., displace) Remicade and Bristol-Myers Squibb's Orencia.  

The core efficacy messages of Actemra's professional marketing campaign resonate strongly with rheumatologists. Based on a quantitative derived importance analysis supported by qualitative interviews with physicians, these core messages have a direct influence on physicians' perceptions of biologic performance in their clinical practice. In some instances, these efficacy attributes are competitive advantages for Actemra over other biologic agents.  

This study represents the final wave of LaunchTrends: Actemra. Trends are compared over time including trial and usage of Actemra, patient types, line of therapy, product perceptions, promotional detailing and messaging, and perceptions of manufacturers' co-pay assistance programs. Post-launch tracking of Actemra and the market dynamics for the biologic class will continue to be covered in the TreatmentTrends®: Rheumatoid Arthritis series and ChartTrends®: Biologics in Rheumatoid Arthritis, a 1,000+ patient chart review that compares actual treatment patterns with self-reported physician response.  

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Sharon Funk404-223-2963sfunk@bio-trends.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Report by BioTrends Research Group To Highlight The Launch Of ACTEMRA (tocilizumab)
2. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
3. Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
4. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
5. Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
6. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
7. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):